ProCE Banner Activity

Expert Guidance for the Treatment of Myelofibrosis

Tool

Use this Interactive Decision Support Tool to compare your choices of therapy for patients with myelofibrosis with those of 5 renowned experts.

Released: May 08, 2023

Share

Faculty

Prithviraj Bose

Prithviraj Bose, MD

Associate Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

John Mascarenhas

John Mascarenhas, MD

Director, Adult Leukemia Program
Leader, Myeloproliferative Disorders Clinical Research Program
Division of Hematology/Oncology
Tisch Cancer Institute 
Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York

Ruben A. Mesa

Ruben A. Mesa, MD

President
Enterprise Cancer Service Line
Executive Director
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Enterprise Senior Vice President
Atrium Health
Vice Dean for Cancer Programs
Wake Forest University School of Medicine
Professor of Medicine
Wake Forest University School of Medicine
Winston-Salem, North Carolina

Raajit K. Rampal

Raajit K. Rampal, MD, PhD

Associate Member
Director
MPN and Rare Hematologic Malignancies Program
Director
Center for Hematologic Malignancies
Memorial Sloan Kettering Cancer Center
New York, New York

Brady L. Stein

Brady L. Stein, MD, MHS

Professor of Medicine
Department of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Provided by

ProCE Banner

Supporters

Supported by educational grants from

GSK

Incyte Corporation

PharmaEssentia Corp